The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. This space is growing at an exponential pace and is expected to reach $100 billion by 2030.
The soaring demand for weight-loss drugs has pushed companies to innovate beyond GLP-1s. One emerging area of interest is cannabinoid (CBD)-based therapies, which may unlock new mechanisms for managing weight and metabolic conditions.
Like obesity, cannabis is among the fastest-growing industries globally. While this industry is expected to surpass the $200 billion mark by 2032, investing directly in pure-play cannabis companies has often been disappointing for investors, largely due to regulatory complexities.
